CF
TEVA icon

Corebridge Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Corebridge Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-165,493
Closed -$2.54M – 2510
2025
Q1 		$2.54M Sell
165,493
-8,694
-5% -$155K 0.01% 896
2024
Q4 		$3.84M Sell
174,187
-4,050
-2% -$73.7K 0.02% 797
2024
Q3 		$3.21M Buy
178,237
+918
+0.5% +$16.1K 0.02% 878
2024
Q2 		$2.88M Buy
+177,319
New +$2.73M 0.02% 884

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Corebridge Financial's TEVA Position: Q2 2025 in Review

Corebridge Financial sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 165,493 shares — an estimated $2.54M sold.

Corebridge Financial first reported a position in TEVA in Q2 2024 and held it in 4 quarters. The position peaked at $3.84M in Q4 2024. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Corebridge Financial reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 165,493 Teva Pharmaceuticals shares in Q2 2025, an estimated $2.54M.
  • Corebridge Financial first reported a position in Teva Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Teva Pharmaceuticals position peaked at $3.84M in Q4 2024.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.